Download PDF
Thromb Haemost 1961; 6(01): 015-024
DOI: 10.1055/s-0038-1654535
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

The Effect of Dextran of Various Molecular Weight on the Coagulation in Dogs

Sven Erik Bergentz
1   Department of Surgery II, University of Göteborg, Sahlgrenska Sjukhuset, Göteborg; Department of Surgery, University of Lund, Allmänna Sjukhuset, Malmö Department of Medicine, University of Lund, Allmänna Sjukhuset, Malmö, Sweden
,
Oddvar Eiken
1   Department of Surgery II, University of Göteborg, Sahlgrenska Sjukhuset, Göteborg; Department of Surgery, University of Lund, Allmänna Sjukhuset, Malmö Department of Medicine, University of Lund, Allmänna Sjukhuset, Malmö, Sweden
,
Inga Marie Nilsson
1   Department of Surgery II, University of Göteborg, Sahlgrenska Sjukhuset, Göteborg; Department of Surgery, University of Lund, Allmänna Sjukhuset, Malmö Department of Medicine, University of Lund, Allmänna Sjukhuset, Malmö, Sweden
› Author Affiliations
Further Information

Publication History

Publication Date:
12 July 2018 (online)

Also available at
    Permissions and Reprints

Summary

1. Infusions of low molecular weight dextran (Mw = 42 000) to dogs in doses of 1—1.5 g per kg body weight did not produce any significant changes in the coagulation mechanism.

2. Infusions of high molecular weight dextran (Mw = 1 000 000) to dogs in doses of 1—1.5 g per kg body weight produced severe defects in the coagulation mechanism, namely prolongation of bleeding time and coagulation time, thrombocytopenia, pathological prothrombin consumption, decrease of fibrinogen, prothrombin and factor VII, factor V and AHG.

3. Heparin treatment of the dogs was found to prevent the decrease of fibrinogen, prothrombin and factor VII, and factor V otherwise occurring after injection of high molecular weight dextran. Thrombocytopenia was not prevented.

4. In in vitro experiments an interaction between fibrinogen and dextran of high and low molecular weight was found to take place in systems comprising pure fibrinogen. No such interaction occurred in the presence of plasma.

5. It is concluded that the coagulation defects induced by infusions of high molecular weight dextran are due to intravascular coagulation.

 

  • References

  • (1) Adant M. Quelques effets de l’injection intraveineuse de dextran et de polyvinylpyrrolidone au chien normal ou hépatectomisé. Bull. Acad. roy. Méd. Belg. 19: 264 1954;
    PubMedSearch in Google Scholar
  • (2) Adelson E. Bleeding time prolongation after dextran infusion. Bibl. haemat (Basel) 7: 275 1958;
    PubMedSearch in Google Scholar
  • (3) Adelson E, Crosby W. H, Roeder W. H. Further studies of a hemostatic defect caused by intravenous dextran. J. Lab. clin. Med. 45: 441 1955;
    PubMedSearch in Google Scholar
  • (4) Bergentz S.-E, Nilsson I. M. Changes in coagulation and fibrinolysis occurring in dogs after trauma. Acta chir. scand.. In press 1961
    PubMedSearch in Google Scholar
  • (5) Blombäck B, Blombäck M. Purification of human and bovine fibrinogen. Ark. Kemi 10: 415 1956;
    PubMedSearch in Google Scholar
  • (6) Bronwell A. W, Artz C. P, Sako Y. Evaluation of blood loss from standardized wound after dextran. Surg. Forum 5: 809 1954;
    PubMedSearch in Google Scholar
  • (7) Carbone T. V, Furth F. W, Scoll Jr R, Crosby W. H. An haemostatic defect associated with dextran infusion. Proc. Soc. exp. Biol. (N. Y.) 85: 101 1954;
    CrossrefPubMedSearch in Google Scholar
  • (8) Ellis Jr P, Kleinsasser R, LeRoy J, Speer R. J. Changes in coagulation occurring in dogs during hypothermia and cardiac surgery. Surgery 41: 198 1957;
    PubMedSearch in Google Scholar
  • (9) Fletcher F, Martin L, Ratcliffe A. Interaction of macromolecules and fibrinogen. Nature 170: 319 1952;
    PubMedSearch in Google Scholar
  • (10) Gelin L. E. Studies in anemia of injury. Acta dur. scand. Suppl. 210 1956;
    PubMedSearch in Google Scholar
  • (11) Howard J. M, Teng C. T, Loeffler R. K. Studies of dextrans of various molecular sizes. Ann. Surg. 143: 369 1956;
    CrossrefPubMedSearch in Google Scholar
  • (12) Horvath S. M, Hamilton L. H, Spurr G. B, Allbaugh E. B, Hutt B. K. Plasma expanders and bleeding times. J. appl. Physiol. 7: 614 1954;
    PubMedSearch in Google Scholar
  • (13) Hummel K, Halse T. Theoretische Grundlagen der blutstillenden Wirkung von Kolloiden. Klin. Wschr. 30: 688 1952;
    CrossrefPubMedSearch in Google Scholar
  • (14) Jacobaeus U. The effect of dextran on the coagulation of blood. Acta med. scand. 6: 505 1955;
    PubMedSearch in Google Scholar
  • (15) Jacobaeus U. Studies on the effect of dextran on the coagulation of blood. Acta med. scand. Suppl. 157 1957;
    PubMedSearch in Google Scholar
  • (16) Jaenike J, Waterhouse C. Metabolic and hemodynamic changes induced by the prolonged administration of dextran. Circulation 11: 1 1955;
    CrossrefPubMedSearch in Google Scholar
  • (17) Langdell R. D, Adelson E, Furth F. W, Crosby W. H. Dextran and prolonged bleeding time. J. Amer. med. Ass. 166: 346 1958;
    CrossrefPubMedSearch in Google Scholar
  • (18) Laurell A. B. Influence of dextran on the conversion of fibrinogen to fibrin. Scand. J. clin. Lab. Invest. 3: 262 1951;
    CrossrefPubMedSearch in Google Scholar
  • (19) Long D, Sanches L, Vareo R. L, Lillehei W. The use of Low Molecular Weight Dextran and Serum Albumin as plasma expanders in Extracorporeal Circulation. To be published.
    PubMed
  • (20) Nilsson I. M, Blombäck M, Francken I. v. On an inherited autosomal hemorrhagic diathesis with antihemophilic globulin (AHG) deficiency and prolonged bleeding time. Acta med. scand. 159: 35 1957;
    PubMedSearch in Google Scholar
  • (21) Nilsson I. M, Olow B. Streptokinase induced fibrinolysis in man. Acta chir. scand.. To be published.
    PubMed
  • (22) Nilsson I. M, Sjoerdsma A, Waldenström J. Antifibrinolytic activity and metabolism of ε-aminocaproic acid in man. Lancet 1: 1322 1960;
    PubMedSearch in Google Scholar
  • (23) Ricketts C. R. Interaction of dextran and fibrinogen. Nature 169: 970 1952;
    PubMedSearch in Google Scholar
  • (24) Ross S, Ebert R. Microelectrophoresis of blood platelets and the effects of dextran. J. clin. Invest. 38: 155 1959;
    CrossrefPubMedSearch in Google Scholar
  • (25) Rothman S, Adelson E, Schwebel A, Langdell R. D. Adsorption of carbon-14 dextran to human blood platelets and red blood cells, in vitro. Vox Sang. (Basel) 2: 104 1957;
    PubMedSearch in Google Scholar
  • (26) Scott J. S. Blood coagulation failure in obstetrics. Brit. med. J. 2: 290 1955;
    CrossrefPubMedSearch in Google Scholar
  • (27) Semple R. The effects of single large infusions of various dextran solutions on hypovolemic dogs. Canad. J. Biochem. 32: 670 1954;
    PubMedSearch in Google Scholar
  • (28) Semple R. Changes in protein fractions of dog plasma after bleeding and dextran infusion. J. Lab. clin. Med. 45: 61 1955;
    PubMedSearch in Google Scholar
  • (29) Swank R. Suspension stability of the blood after injections of dextran. J. appi. Physiol. 12: 125 1958;
    PubMedSearch in Google Scholar